Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.33 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766191 | 0.79 | HCAR3 (0.48) | KDM4EMAPTALDH1A1L3MBTL1KCNJ1 | |
| SCHEMBL30753556 | 0.79 | HCAR3 (0.48) | KDM4EMAPTALDH1A1L3MBTL1KCNJ1 | |
| SCHEMBL19630947 | 0.76 | HCAR3 (0.54) | KDM4ELMNAALDH1A1L3MBTL1KCNJ1 | |
| SCHEMBL16436147 | 0.75 | CYP11B1 (0.46) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2911125 | 0.75 | RAB9A (0.46) | KDM4EMAPTLMNAMEN1KMT2A | |
| SCHEMBL29956458 | 0.75 | KDM4E (0.39) | KDM4EALDH1A1L3MBTL1KCNJ1POLB | |
| SCHEMBL6890594 | 0.75 | ALDH1A1 (0.36) | KDM4EGAAMAPTLMNAMEN1 | |
| SCHEMBL29958408 | 0.75 | HCAR3 (0.53) | KDM4EALDH1A1L3MBTL1KCNJ1FDPS | |
| Benzaldehyde SCHEMBL27567924 | 0.73 | HCAR3 (0.55) | ALDH1A1 | |
| SCHEMBL10548812 | 0.73 | HCAR3 (0.56) | KDM4EMAPTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2013-06-13 | — | — | US | claimed |
| US-8440841-B2 | 5-pyrrolidinylsulfonyl isatin derivatives | Universitätsklinikum Münster (DE) | 2013-05-14 | — | — | US | claimed |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2009-02-12 | — | — | US | claimed |
| EP-1841759-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2007-10-10 | — | — | EP | claimed |
| WO-2006074799-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2006-07-20 | — | — | WO | claimed |
| WO-2024102956-A1 | KETO-AMIDE-BASED FIBROBLAST ACTIVATION PROTEIN-TARGETED LIGAND LINKED TO AN IMAGING OR THERAPEUTIC AGENT, COMPOSITIONS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-117209476-A | The method comprises the following steps of 99m Tc-labeled radioactive probe for targeting fibroblast activation protein and preparation method and application thereof | 中山大学附属第一医院 | 2023-12-12 | — | — | CN | disclosed |
| EP-4126841-B1 | COMPOUNDS FOR INHIBITION OF FIBROBLAST ACTIVATION PROTEIN | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2023-09-27 | — | — | EP | disclosed |
| WO-2021197519-A1 | COMPOUNDS FOR INHIBITION OF FIBROBLAST ACTIVATION PROTEIN | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2021-10-07 | — | — | WO | disclosed |
| CN-104800865-A | Targeted positron tracer for realizing PET (Positron Emission Tomography) imaging of positive tumors for HER2 (Human Epidermal Growth Factor Receptor 2) expression, and preparation method of targeted positron tracer | FIRST AFFILIATED HOSPITAL MEDICAL COLLEGE XI AN JIAOTONG UNIV | 2015-07-29 | — | — | CN | disclosed |
| CN-104800865-A | Targeted positron tracer for realizing PET (Positron Emission Tomography) imaging of positive tumors for HER2 (Human Epidermal Growth Factor Receptor 2) expression, and preparation method of targeted positron tracer | FIRST AFFILIATED HOSPITAL MEDICAL COLLEGE XI AN JIAOTONG UNIV | 2015-07-29 | — | — | CN | disclosed |
| CN-104031139-A | Positive electron medicine for alzheimers disease PET (Positron Emission Tomography) imaging and preparation method of positive electron medicine | FIRST AFFILIATED HOSPITAL MEDICAL COLLEGE XI AN JIAOTONG UNIV | 2014-09-10 | — | — | CN | disclosed |
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2013-06-13 | — | — | US | disclosed |
| US-8440841-B2 | 5-pyrrolidinylsulfonyl isatin derivatives | Universitätsklinikum Münster (DE) | 2013-05-14 | — | — | US | disclosed |
| EP-0862464-B1 | AMINO ACID ANALOGS FOR TUMOR IMAGING | UNIV EMORY (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-1841759-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074799-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2006-07-20 | — | — | WO | disclosed |
| EP-1068222-A1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION AND FOR IMAGING AND TREATMENT OF CANCER | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999051628-A1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION AND FOR IMAGING AND TREATMENT OF CANCER | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | CASP5, SLC1A5, CTSZ | KDM4E 4132/4885GAA 2298/4885MAPT 3084/4885 |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | CASP5, CTSZ, CTSS | KDM4E 4029/4885GAA 2120/4885MAPT 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.